Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

AMG 757 × Genitourinary × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Endocrine 2 NET 1 Genitourinary 1

Conditions

Neuroendocrine Prostate Cancer 1

Interventions

pembrolizumab 163 Magnetic Resonance Spectroscopy 150 Specimen Handling 123 enzalutamide 116 Nivolumab 113 Docetaxel 90 Gemcitabine 87 Radiosurgery 84 Prednisone 83 Abiraterone Acetate 83 Radiotherapy 70 Androgen Antagonists 70 apalutamide 64 Cisplatin 63 Biopsy 58 Ipilimumab 57 Carboplatin 54 cabozantinib 52 Leuprolide 52 darolutamide 50 abiraterone 46 Radiation 46 Pluvicto 42 enfortumab vedotin 40 Standard of Care 39 atezolizumab 38 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37 Goserelin 34 X-Rays 33 olaparib 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed

41 enrolled 19 charts

EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡